Most pharma review processes weren't designed. They evolved — from a combination of regulatory requirements, internal habits, and workarounds that accumulated over years of product launches and compliance crises. The result, in many organisations, is a process that looks robust on paper but generates exactly the kind of risk it was built to prevent.
Here are five signs that your review process is the problem, not the solution.
If your review workflow involves attaching documents to emails, receiving annotated PDFs back from multiple stakeholders, and reconciling those comments manually, you are operating without version control. The practical consequence is that reviewers are frequently commenting on different iterations of the same document. Email-based routing and spreadsheet tracking remain among the most consistently cited causes of missed approvals and version confusion in pharmaceutical marketing and labeling workflows — a pattern that persists across organisation sizes and therapeutic areas.
An approval that references "Version 7 of the EU SmPC insert" is meaningfully different from an approval that references a specific, hash-verified file. When sign-offs aren't tied to a precise, unambiguous document state, there is always the possibility that the document changed between review and submission. This is a documented failure pattern in pharmaceutical labeling workflows, and it is one of the root causes of the "correct approval, wrong document" recalls that appear periodically in FDA enforcement records.
If your process regularly includes revision requests that arrive after a document has received final sign-off — changes that require a new round of review, or that are made informally without restarting the formal approval cycle — your process has a boundary problem. The formal sign-off is not being treated as a genuine gate. This typically indicates that the upstream review process isn't catching all the issues it should, forcing late-stage interventions that bypass the controls the process was designed to enforce.
Manual visual comparison of pharmaceutical artwork is the weakest possible form of proofreading for a document that may contain hundreds of data points across multiple languages. The documented error categories that human review consistently misses include missing characters that alter dosage values, missing punctuation that changes dosage frequency, and text that has been flattened into an image and stripped of its Unicode content. None of these are reliably visible on a printed page or a screen preview. The only reliable method for catching them is character-level automated comparison against the approved master.
Compliance findings related to electronic records and signatures remain widespread among regulated pharmaceutical firms — and they typically don't arise from deliberate non-compliance. They arise from audit trail implementations that don't meet the specific requirements of 21 CFR Part 11. An audit trail that documents who approved something, but not precisely what was approved, is not audit-trail compliant. The specific requirement — a secure, computer-generated, time-stamped record of who made changes, what changed, and when — is the foundation of defensible compliance.
If any of these five signs are familiar, the issue isn't the people in your review process. It's the infrastructure they're working within.
↗ InformaIT's Content Compare replaces error-prone manual review with automated, audit-trail-documented document comparison. Book a demo.